Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · President and CEO | August 17, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date August 17, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,775 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 5,062 · Balance 132,775 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 26, 2026 23:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,062 | $8.08 | $40,882.74 |
DisclosureSEC source: 0000905148-26-003960 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,775 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,241 | $9.13 | $47,844.56 |
DisclosureSEC source: 0000905148-26-002571 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,837 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 81,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001225 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,078 F1 · shares: These restricted stock units ("RSUs") vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following March 9, 2026, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous employment. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,442 | $5.09 | $7,335.45 |
DisclosureSEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 4 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,978 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,298 | $5.09 | $6,601.63 |
DisclosureSEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 3 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,420 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 58 | $5.08 | $294.64 |
DisclosureSEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 2 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,718 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 198 | $5.08 | $1,005.64 |
DisclosureSEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,776 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 56 | $13.19 | $738.53 |
DisclosureSEC source: 0000905148-25-004141 · form4.xml · nonDerivative · entry 2 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,974 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,859 | $13.19 | $37,698.77 |
DisclosureSEC source: 0000905148-25-004141 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,030 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,620 | $11.62 | $18,819.54 |
DisclosureSEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 3 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,889 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,281 | $11.62 | $14,878.82 |
DisclosureSEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 2 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,509 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 57 | $11.61 | $661.94 |
DisclosureSEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,790 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,276 | $6.76 | $22,155.59 |
DisclosureSEC source: 0000905148-25-001865 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,847 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2025 and May 19, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,331 | $7.00 | $23,307.01 |
DisclosureSEC source: 0000905148-25-000865 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,123 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:04 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,664 | $11.20 | $18,633.47 |
DisclosureSEC source: 0000905148-24-003241 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,454 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 18, 2024 and November 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:03 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-002545 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,118 F1 · shares: These restricted stock units ("RSUs") vest as to 1/12th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following September 9, 2024, and as to 1/12th of the total number of shares (rounded down to the next whole number of shares) on each of the next eleven Quarterly Vesting Dates, such that all of the shares subject to the RSUs on the grant date shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 56 | $6.63 | $371.34 |
DisclosureSEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 3 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,118 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 297 | $6.63 | $1,969.11 |
DisclosureSEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 2 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,174 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,468 | $6.63 | $9,731.37 |
DisclosureSEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,471 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 42,899 | $0.62 | $26,468.68 |
DisclosureSEC source: 0000905148-24-001560 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898,498 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,746 | $0.72 | $7,737.12 |
DisclosureSEC source: 0000905148-24-000910 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 941,397 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 675,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000114 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 952,143 F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 22:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,856 | $0.39 | $3,444.98 |
DisclosureSEC source: 0000905148-23-001512 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,143 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,277 | $1.65 | $15,334.88 |
DisclosureSEC source: 0001140361-23-040561 · form4.xml · nonDerivative · entry 2 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,999 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,849 | $1.65 | $9,662.55 |
DisclosureSEC source: 0001140361-23-040561 · form4.xml · nonDerivative · entry 1 Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,276 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.